Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential

Area of Science:

• Hematologic Malignancies
• Molecular Biology
• Cancer Genomics

Background:

• Multiple myeloma (MM) is a hematologic malignancy with variable clinical outcomes.
• Genetic and epigenetic factors contribute to MM tumor dynamics.
• Accurate prognostic biomarkers are needed to improve patient management.

Purpose of the Study:

• To identify biomarkers for improved prognosis assessment in multiple myeloma.
• To analyze microRNA (miRNA) and gene expression profiles in MM patients.
• To correlate molecular markers with MM prognosis and non-cancerous blood diseases (NCBD).

Main Methods:

• miRNA sequencing of bone marrow (BM) samples from MM patients.
• Real-time reverse transcription polymerase chain reaction (RT-PCR) for miRNA and gene expression analysis (ASF1B, CD82B, CRISP3, FN1, MEF2B, PD-L1, PPARγ, TERT, TIMP1, TOP2A, TP53).
• Comparison of expression levels between MM patients (favorable/unfavorable prognosis) and NCBD controls.

Main Results:

• Significant differences in miRNA expression (e.g., increased miRNA-124, -138, -10a, -126, -143, -146b, -20a, -21, -29b, let-7a; decreased miRNA-96) between MM and NCBD groups.
• Altered gene expression in MM vs. NCBD: decreased ASF1B, CD82B, CRISP3; increased FN1, MEF2B, PDL1, PPARγ, TERT.
• Favorable prognosis MM showed decreased TIMP1 and increased CD82B, CRISP3 expression compared to unfavorable prognosis MM.
• No significant miRNA differences between favorable and unfavorable MM prognosis groups.

Conclusions:

• The CRISP3/TIMP1 expression ratio is a promising prognostic biomarker for multiple myeloma.
• MM development involves complex molecular pathways influenced by genetic and epigenetic interplay.
• Further research into these molecular pathways could lead to novel therapeutic strategies.